APR 07, 2015 08:30 AM PDT

Diabetic Cardiomyopathy Modeling & Screening with iPSC Cardiomyocytes

  • Senior Director of Cell Biology Research and Development, Cellular Dynamics International (CDI)
      Brad Swanson, PhD

      Dr. Swanson is Senior Director of Cell Biology Research and Development at Cellular Dynamics International (CDI) where he led the effort to develop the first commercially available hiPSC-derived cell product, iCell® Cardiomyocytes, and several other hiPSC models including cortical neurons, dopaminergic neurons, skeletal muscle, cardiac progenitors, and astrocytes. Prior to CDI, Dr. Swanson was a Senior Scientist at Roche NimbleGen, where he established, among other items, the industry's first sequence capture product for targeted next generation sequencing workflows. He started his industry career at Promega as a Senior Scientist developing small molecule high-throughput screening products. Dr. Swanson received his PhD in Cellular and Molecular Biology (cardiac differentiation) from UW-Madison, undertook postdoctoral research in T cell behavior at the National Jewish Medical Center-HHMI in Denver, Colorado, and joined Columbus Children's Research Institute/Ohio State University Center for Vaccines and Immunity as an Assistant Professor.
    • Pharma and Research Development (pRED), Hoffmann-La Roche, Inc
        Roberto Iacone, PhD

        Dr. Roberto Iacone is a Senior Principal Scientist at Roche, pharma and research development (pRED) - Basel, in the Neuroscience, Ophthalmology and Rare Disease DTA. He has a medical background and a strong research experience in Stem Cell Biology. He established the Stem Cell Group in the Cardiovascular and Metabolic Discovery at Roche where research in his group has been directed at understanding the pathophysiological mechanisms and development complications in the heart using patient specific iPSCs: "the patient in a dish" paradigm. Recently the group is establishing in vitro disease modeling to identify new drugs for the retina remodeling linked to age-related macular degeneration (AMD). His research interest includes the identification and characterization of genes that regulate tissue repair and regeneration, aiming to develop regenerative medicines activating endogenous tissue progenitors.

      Date: Tuesday, April 7th, 2015
      Time: 8:30AM PST, 11:30AM EST, 5:30PM CET

      The development of new medicines for Diabetes Type 2 complications has proven to be challenging due to the use of cellular models that recapitulate some subsets of the specific features of the human disease. Herewith, we develop environmentally and genetically driven in vitro models of the condition using human induced pluripotent stem cell-derived cardiomyocytes. First, we mimic diabetic clinical chemistry to induce a phenotypic surrogate of diabetic cardiomyopathy, observing structural and functional disarray. Next, we consider genetic effects by deriving cardiomyocytes from diabetic patients with variable disease progression. In this work, we present the first patient-specific iPSC model of a complex metabolic condition, showing the power of this technique for discovery and testing of new therapeutic strategies. We conclude presenting a new approach using chemical biology to ultimately elucidate novel mechanisms activating cardiomyocytes repair and regeneration.

      Show Resources
      Show Resources
      Connect with us